NEW YORK, Sept. 15, 2005 (PRIMEZONE) -- Amersin Life Science Corporation (OTCBB:AMLS) Chief Executive Officer, H.Y. (Reid) Li, announced that the company notified the minority partners in its Hubei Tongji Benda Ebei Pharmaceutical Co. Ltd. joint venture in Hubei Province China today, that it did not believe it would be in the best interest of its shareholders to advance additional funds to complete acquisition of its interest or to provide additional working capital. It is anticipated that discussions and negotiations will take place over the next several weeks which may lead to the company holding a minority position in the Joint Venture, selling its interest in the joint venture back to the vendors (a company controlled by the minority partners) or other outcome which is not yet determined. Additional information will be made available once a definitive agreement has been determined.
"Safe Harbor" Statement:
This news release contains certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from the forward-looking statements contained herein. Detailed information about many risk factors are set forth in Amersin's periodic filings with the Securities and Exchange Commission including, but not limited to, those risks and uncertainties listed in the sections entitled "Cautionary Note Regarding Forward-Looking Statements" and "Management's Discussion and Analysis" in Amersin's most recent Quarterly Report on Form 10-QSB. All documents are available through the SEC's Electronic Data Gathering Analysis and Retrieval system (EDGAR) at http://www.sec.gov or the Amersin web site at http://www.amersin.com. Amersin is under no obligation, and expressly disclaims any obligation, to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
The Amersin Life Sciences Corp. logo is available at: http://www.primezone.com/newsroom/prs/?pkgid=1616